Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H01:13

meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for the...
Combinatorial Gene Control02:33

Combinatorial Gene Control

Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.

Breast cancer research : BCR·2026
Same author

Safety of concurrent T-DM1 and radiation therapy in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.

International journal of radiation biology·2026
Same author

Different event-related potential responses during face processing between siblings of autistic individuals and neurotypical infants: A systematic review and meta-analysis.

Neuroscience and biobehavioral reviews·2026
Same author

The United Kingdom National Programme of DCD heart transplantation: Timings, techniques, feasibility, and outcomes with abdominal normothermic regional perfusion.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Expanding the Spectrum of Ubiquitin-specific Proteases-Fused Neoplasms: A Clinicopathologic and Molecular Study of USP2- and USP8-Rearranged Spindle Cell Tumors.

The American journal of surgical pathology·2026
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

[MET: new target, new combinations].

Camille Serrate1, Sarah Watson, Stéphane Vignot

  • 1Hôpital Saint-Louis, service d'oncologie médical, Paris, France.

Bulletin Du Cancer
|May 31, 2011
PubMed
Summary
This summary is machine-generated.

The MET receptor tyrosine kinase drives tumor development and invasion. MET inhibitors show promise, especially in combination therapies for aggressive cancers.

More Related Videos

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks
07:50

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks

Published on: November 25, 2015

New Variations for Strategy Set-shifting in the Rat
09:45

New Variations for Strategy Set-shifting in the Rat

Published on: January 23, 2017

Related Experiment Videos

Last Updated: Jun 1, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks
07:50

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks

Published on: November 25, 2015

New Variations for Strategy Set-shifting in the Rat
09:45

New Variations for Strategy Set-shifting in the Rat

Published on: January 23, 2017

Area of Science:

  • Oncology and Molecular Biology: Focuses on the MET receptor tyrosine kinase and its role in cancer progression.

Context:

  • The MET pathway is crucial in embryonic development and tissue repair.
  • Aberrant MET signaling is linked to aggressive tumors, driving cell migration, invasion, and epithelial-to-mesenchymal transition.
  • MET amplification or mutation is observed in various cancers, correlating with poor prognosis.

Purpose:

  • To explore the role of the MET receptor tyrosine kinase in tumor development.
  • To evaluate the potential of MET inhibitors as a therapeutic strategy.
  • To investigate MET inhibition in combination with other drugs for enhanced efficacy.

Summary:

  • The MET receptor tyrosine kinase plays a significant role in tumor progression by promoting cell migration, invasion, and epithelial-to-mesenchymal transition.
  • Preliminary clinical studies of MET inhibitors have yielded encouraging results, particularly in tumors with MET amplification or mutation.
  • MET activation can be a secondary event triggered by hypoxia, cytokines, or HER inhibitors, suggesting that MET inhibition could be beneficial in combination therapies.

Impact:

  • MET inhibitors represent a promising targeted therapy approach for aggressive cancers.
  • Combination therapies involving MET inhibitors may overcome resistance mechanisms and improve patient outcomes.
  • Targeting the MET pathway offers a potential strategy to manage cancers with poor prognosis and aberrant MET signaling.